<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172403</url>
  </required_header>
  <id_info>
    <org_study_id>1708054</org_study_id>
    <secondary_id>ANSM</secondary_id>
    <nct_id>NCT03172403</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Expression of Myostatin and Colon Cancer Associated Cachexia</brief_title>
  <acronym>MYOCAC</acronym>
  <official_title>Skeletal Muscle Expression of Myostatin and Colon Cancer Associated Cachexia(MYOCAC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer cachexia is responsible for the death of approximately 20% of patients. Myostatin is a
      master negative regulator of skeletal muscle mass. If the role of myostatin in cancer
      cachexia is now well established in murine models, no study has focused on muscle expression
      of Myostatin in relation to the degree of cachexia. the hypothesize is that muscle Myostatin
      a biological marker of cachexia in patients with colon cancer. The main objective is to
      compare skeletal muscle Myostatin messenger RiboNucleic Acid (mRNA) level as a function of
      cachexia in colon cancer patients. Myostatin messenger RiboNucleic Acid (mRNA) level will be
      determined in a muscle sample taken during the resection under general anaesthesia. Skeletal
      muscle index will be determined before surgery, 3 and 6 months after surgery. Muscle strength
      of the lower and upper limbs will be determined before resection, at 1 month, 3 months and 6
      months postoperatively. Blood sampling will also be performed on these 4 occasions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between skeletal muscle and degree myostatin</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluate correlation between skeletal muscle force/index and degree myostatin. Skeletal muscle force/index will be determinated by skeletal muscle force/index results.
Degree myostatin will be determinated by blood samples with Enzyme Linked ImmunoSorbent Assay (ELISA) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between skeletal muscle force and index before resection surgery</measure>
    <time_frame>Baseline from 7 months</time_frame>
    <description>Evaluate Correlation between skeletal muscle force and index before resection surgery to estimate the extent of cachexia-induced muscle dysfunction by results tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between level of myostatin muscular expression and degree myostatin</measure>
    <time_frame>Month 2</time_frame>
    <description>Evaluate correlation between level of myostatin muscular expression and degree myostatin.
Level of myostatin muscular expression will be determinated by muscle biopsy. Degree myostatin will be determinated by blood samples with Enzyme Linked ImmunoSorbent Assay (ELISA) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery</measure>
    <time_frame>Month 2</time_frame>
    <description>Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery</measure>
    <time_frame>Month 4</time_frame>
    <description>Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery</measure>
    <time_frame>Month 7</time_frame>
    <description>Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis level of myostatin muscular expression and blood samples results</measure>
    <time_frame>Month 2</time_frame>
    <description>Analysis level of myostatin muscular expression and blood samples results according to cancer stage, neoadjuvant treatment and chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with colon cancer requiring resection surgery will be included. They will have measure of height and weight, blood samples, skeletal muscle force, skeletal muscle index and muscle biopsy.
V1: Inclusion will be effectuated at the time of anaesthetic consultation V2: The day before and day of resection surgery about 1 month after V3: Follow-up at 1 month V4: Follow-up at 3 months V6: Follow-up at 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Height and weight</intervention_name>
    <description>Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)</description>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)</description>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skeletal muscle force</intervention_name>
    <description>Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)</description>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skeletal muscle index</intervention_name>
    <description>Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)</description>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Muscle biopsy</intervention_name>
    <description>Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)</description>
    <arm_group_label>Patients with colon cancer requiring resection surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men aged 40-80.

          -  First diagnosis for colon cancer requiring surgery with neoadjuvant treatment or not.

          -  Signature of consent

          -  Affiliate or beneficiary of social security

        Exclusion Criteria:

          -  Administration of corticosteroids.

          -  Thyroid disease treated.

          -  Severe chronic pathology during treatment (neuro-muscular pathologies, renal
             insufficiency requiring dialysis, COPD under continuous oxygen therapy).

          -  Psychological, familial, social or geographical conditions that could affect the
             participation of the subject throughout the duration of the protocol.

          -  BMI&gt; 30 due to the difficulty of interpretation of BMI variations in obese patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine ABBOUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karine ABBOUD, MD</last_name>
    <phone>(0)477828337</phone>
    <phone_ext>+33</phone_ext>
    <email>Karine.abboud@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON, CRA</last_name>
    <phone>(0)477829458</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karine ABBOUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TIFFET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cachexia</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Myostatin</keyword>
  <keyword>Skeletal muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

